Showing results (31-40 of 130) with videos related to
Sort By:
Pageof 13
Journal of Medical Economics|July 18, 2019
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UKStephen C Bain, Brian Bekker Hansen, Barnaby Hunt, et al.Diabetes, Obesity & Metabolism|October 27, 2018
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UKAdie Viljoen, Christina S Hoxer, Pierre Johansen, et al.Cardiovascular Diabetology|October 1, 2020
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trialsMansoor Husain, Stephen C Bain, Anders Gaarsdal Holst, et al.Frontiers in Endocrinology|September 23, 2022
The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cellOlivia McCarthy, Signe Schmidt, Merete Bechmann Christensen, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 20, 2015
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin TherapyNick Freemantle, Muhammad Mamdani, Tina Vilsbøll, et al.Nutrients|July 25, 2019
Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?Olivia McCarthy, Othmar Moser, Max L Eckstein, et al.Medicine and Science in Sports and Exercise|June 15, 2021
Pancreatic β-Cell Function Is Associated with Augmented Counterregulation to In-Exercise Hypoglycemia in Type 1 DiabetesOlivia McCarthy, Jason Pitt, Max L Eckstein, et al.Journal of Sports Sciences|April 15, 2010
Heart rate prescribed walking training improves cardiorespiratory fitness but not glycaemic control in people with type 2 diabetesRichard D Morton, Daniel J West, Jeffrey W Stephens, et al.Journal of Sports Sciences|May 25, 2010
Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetesDaniel J West, Richard D Morton, Stephen C Bain, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 17, 2022
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UKAdie Viljoen, Barrie Chubb, Samuel J P Malkin, et al.Pageof 13